カレントテラピー　33-1　サンプル page 30/34

このページは カレントテラピー　33-1　サンプル の電子ブックに掲載されている30ページの概要です。
秒後に電子ブックの対象ページへ移動します。
「電子ブックを開く」をクリックすると今すぐ対象ページへ移動します。

概要：
カレントテラピー　33-1　サンプル

70 Current Therapy 2015 Vol.33 No.170lowers body weight in Japanese patients with type 2 diabetesmellitus. ADA2013. #1039P9）Cafelu WT, Leiter LA, Yoon KH, et al：Efficacy and safety ofcanagliflozin versus glimepiride in patients with type 2 diabetesinadequately controlled with metformin（CANTATASU）：52 week results from a randomized, double -blind,phase 3 non-inferiority trial. Lancet 382：941-950, 201310）Henry RR, Murray AV, Marmolejo MH, et al：Dapagliflozin,metformin XR, or both：initial pharmacotherapy for type 2diabetes, a randomised controlled trial. Int J Clin Pract 66：446-456, 201211）Lavalle -Gonzalez FJ, Januszewicz A, Davidson J, et al：Efficacy and safety of canagliflozin compared with placeboand sitagliptin in patients with type 2 diabetes on backgroundmetformin monotherapy：a randomised trial.Diabetologia 56：2582-2592, 201312）Stenlof K, Cefalu WT, Kim KA, et al：Efficacy and safety ofcanagliflozin monotherapy in subjects with type 2 diabetesmellitus inadequately controlled with diet and exercise.Diabetes Obes Metab 15：372-382, 201313）Schernthaner G, Gross JL, Rosenstock J, et al：Canagliflozincompared with sitagliptin for patients with type 2 diabeteswho do not have adequate glycemic control with metforminplus sulfonylurea：a 52-week randomized trial. DiabetesCare 36：2508-2515, 201314）Hagopian K, Ramsey JJ, Weindruch R：Caloric restrictionincreases gluconeogenic and transaminase enzyme activitiesin mouse liver. Exp Gerontol 38：267-278, 200315）Plosker GL：Canagliflozin：a review of Its use in patientswith type 2 diabetes mellitus. Drugs 74：807-824, 201416）Bailey CJ, Gross JL, Pieters A, et al：Effect of dapagliflozin inpatients with type 2 diabetes who have inadequate glycaemiccontrol with metformin：a randomized, double -blind,placebo-controlled trial. Lancet 375：2223-2233, 201017）Bolinder J, Ljunggren O, Johansson L, et al：Dapagliflozinmaintains glycaemic control while reducing weight and bodyfat mass over 2 years in patients with type 2 diabetes mellitusinadequately controlled on metformin. Diabetes ObesMetab 16：159-169, 201418）日本糖尿病学会編・著：糖尿病治療ガイド 2014-2015. p29，文光堂，東京，201419）Merovci A, Solis-Herrera C, Daniele G, et al：Dapagliflozinimproves muscle insulin sensitivity but enhances endogenousglucose production. J Clin Invest 124：509-514, 2014